ARDS vs. SCPS, VAXX, NAVB, EVLO, CMRA, GNCAQ, GNCA, STAB, CALA, and EFTR
Should you be buying Aridis Pharmaceuticals stock or one of its competitors? The main competitors of Aridis Pharmaceuticals include Scopus BioPharma (SCPS), Vaxxinity (VAXX), Navidea Biopharmaceuticals (NAVB), Evelo Biosciences (EVLO), Comera Life Sciences (CMRA), Genocea Biosciences (GNCAQ), Genocea Biosciences (GNCA), Statera Biopharma (STAB), Calithera Biosciences (CALA), and eFFECTOR Therapeutics (EFTR). These companies are all part of the "pharmaceutical products" industry.
Aridis Pharmaceuticals vs.
Scopus BioPharma (NASDAQ:SCPS) and Aridis Pharmaceuticals (NASDAQ:ARDS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations, media sentiment, community ranking and dividends.
9.6% of Aridis Pharmaceuticals shares are held by institutional investors. 5.1% of Scopus BioPharma shares are held by insiders. Comparatively, 5.5% of Aridis Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Aridis Pharmaceuticals received 120 more outperform votes than Scopus BioPharma when rated by MarketBeat users. However, 100.00% of users gave Scopus BioPharma an outperform vote while only 61.00% of users gave Aridis Pharmaceuticals an outperform vote.
Scopus BioPharma has a beta of -0.22, indicating that its share price is 122% less volatile than the S&P 500. Comparatively, Aridis Pharmaceuticals has a beta of 9.8, indicating that its share price is 880% more volatile than the S&P 500.
In the previous week, Scopus BioPharma had 1 more articles in the media than Aridis Pharmaceuticals. MarketBeat recorded 1 mentions for Scopus BioPharma and 0 mentions for Aridis Pharmaceuticals. Scopus BioPharma's average media sentiment score of 0.00 equaled Aridis Pharmaceuticals'average media sentiment score.
Scopus BioPharma has higher earnings, but lower revenue than Aridis Pharmaceuticals.
Summary
Aridis Pharmaceuticals beats Scopus BioPharma on 5 of the 8 factors compared between the two stocks.
Get Aridis Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ARDS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aridis Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:ARDS) was last updated on 3/29/2025 by MarketBeat.com Staff
Buy ARDS Stock Free ARDS Stock Alerts